Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08).
Fiche du document
- doi: 10.1038/s41416-019-0447-0
- issn: 0007-0920
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/s41416-019-0447-0
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30988393
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1532-1827
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6DA91E6BDAAE4
info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/
Sujets proches
Stage Dramatics Histrionics Theatre Professional theater Stage Drama, Modern Plays Drama--Philosophy Stage HistrionicsCiter ce document
A. Curioni-Fontecedro et al., « Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). », Serveur académique Lausannois, ID : 10.1038/s41416-019-0447-0
Métriques
Partage / Export
Résumé
Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CRT) in selected patients (pts) with NSCLC, stage IIIB. Resectable stage IIIB NSCLC received three cycles of CT (cisplatin 100 mg/m 2 and docetaxel 85 mg/m 2 d1, q3w) followed by RT (44 Gy in 22 fractions) with concomitant cetuximab (250 mg/m 2 , q1w) and subsequent surgery. The primary endpoint was 1-year progression-free survival (PFS). Sixty-nine pts were included in the trial. Fifty-seven (83%) pts underwent surgery, with complete resection (R0) in 42 (74%) and postoperative 30 day mortality of 3.5%. Responses were: 57% after CT-cetuximab and 64% after CRT-cetuximab. One-year PFS was 50%. Median PFS was 12.0 months (95% CI: 9.0-15.6), median OS was 21.3 months, with a 2- and 3-yr survival of 41% and 30%, respectively. This is one of the largest prospective phase 2 trial to investigate the role of induction CRT and surgery in resectable stage IIIB disease, and the first adding cetuximab to the neoadjuvant strategy. This trial treatment is feasible with promising response and OS rates, supporting an aggressive approach in selected pts.